FoRx Therapeutics
Frank Zenke is a highly experienced scientific leader in oncology research, currently serving as Chief Scientific Officer at FoRx Therapeutics since August 2023. Prior to this position, Zenke held key roles including Global Head of DNA Damage Response Research at both Merck Healthcare and EMD Serono, Inc., as well as various leadership positions within the Healthcare Business of Merck from 2007 to 2022, focusing on DNA damage response and cellular pharmacology. Earlier experience includes serving as Laboratory Head at Merck KGaA and research roles at The Scripps Research Institute. Zenke earned a Dr. rer. nat. in Biology from the University of Düsseldorf and an Intermediate Diploma in Biology from Ruhr University Bochum.